In Q1 2023, RA Capital Management held 43 positions worth $3.4B. They initiated 43 new positions. Their largest holding was ASND ($745.9M).
Frequently asked questions
What stocks did RA Capital Management own in Q1 2023?
RA Capital Management held 43 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include ASND, PCVX, ETNB, BIIB, CTKB. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RA Capital Management's portfolio worth in Q1 2023?
RA Capital Management's tracked biotech portfolio was worth $3.4B across 43 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RA Capital Management buy in Q1 2023?
RA Capital Management initiated 43 new positions in Q1 2023, including ASND, PCVX, ETNB, BIIB, CTKB and 38 more. They also increased 0 existing positions.
What did RA Capital Management sell in Q1 2023?
RA Capital Management did not fully exit any positions in Q1 2023.
Is RA Capital Management a biotech fund?
Crossover biotech fund that invests from late-stage private through public markets. Known for rigorous scientific analysis and the "biotech social contract" framework. Kolchinsky, a virologist by training, emphasizes understanding drug pricing dynamics and long-term value creation in biotech.
Want AI analysis, insider signals, and catalyst overlays for RA Capital Management?
View latest RA Capital Management portfolio →